Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05044507 · ClinicalTrials.gov registry record · NA

The Efficacy of a Frequency-tuned Electromagnetic Field Treatment in Facilitating the Recovery of Subacute Ischemic Stroke Patients - a Pivotal Study (THE "EMAGINE" STUDY)

A NA study of Ischemic Stroke, sponsored by BrainQ Technologies.

Completed
Registry status
NA
Development phase
100
Enrollment target
15
Study locations

NCT05044507 is a NA study of Ischemic Stroke that has completed, run by BrainQ Technologies. The registered enrollment target is 100 participants, below the 1,462-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (93% lower). The trial reports 15 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05044507, a NA study of Ischemic Stroke, has completed, sponsored by BrainQ Technologies.

COMPLETED
Registry status
NA
Development phase
100 participants
Enrollment target
15
Study locations

Study Summary

This is a multicenter study that will be conducted at approximately 20 centers. BQ 2.0 is a wearable medical device that produces and delivers non-invasive, extremely-low-intensity and low-frequency, frequency-tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery. In this study, BQ 2.0 is intended to reduce disability in adult patients with subacute ischemic stroke, with a moderate to severe disability which includes an upper extremity motor impairment. BQ 2.0 will be used for 9 weeks in conjunction with physical and occupational therapy (PT/OT) and periodic supervision (either remote or in person) of a trained site study team member. Treatments may be administered in multiple settings (e.g. acute care hospital (ACH) or inpatient rehabilitation facilities (IRF), Skilled Nursing Facility (SNF), home or other outpatient setup). The study will enroll up to 150 adult subjects who will be randomly assigned (1:1 allocation ratio) to either active or sham study intervention using BQ 2.0.

Conditions Studied

Interventions

  • DEVICE BQ 2.0

Study Locations (15)

California

  • Rancho Research Institute - Downey
  • Ronald Reagan UCLA Medical Center & California Rehabilitation Institute - Los Angeles

Florida

  • Brooks Rehabilitation Hospital - University Campus - Jacksonville
  • The Miami Project to Cure Paralysis - Miami

New Jersey

  • JFK Johnson Rehabilitation Institute - Edison
  • Kessler Institute of Rehabilitation - West Orange

Texas

  • Baylor Scott & White Institute for Rehabilitation - Dallas
  • TIRR Memorial Hermann Hospital - Houston

District of Columbia

  • MedStar National Rehabililtaion Hospital, - Washington D.C.

Illinois

  • Shirley Ryan Abilitylab - Chicago

Kansas

  • KU Medical Center - Kansas City

Massachusetts

  • Spaulding Rehabilitation Hospital - Boston

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2021-12-04
Est. Completion 2024-01-16
Phase NA

Sponsor

BrainQ Technologies

2 total trials

What the Registry Record Tells You About NCT05044507

The ClinicalTrials.gov registry entry for NCT05044507 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,462-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (93% lower). The listed sponsor is BrainQ Technologies, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Ischemic Stroke appearing as the primary indexed condition, and to 1 intervention - of which BQ 2.0 is the first listed.

NCT05044507 reports 15 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, New Jersey.

Frequently Asked Questions

What is clinical trial NCT05044507 about?

NCT05044507 is a clinical study titled "The Efficacy of a Frequency-tuned Electromagnetic Field Treatment in Facilitating the Recovery of Subacute Ischemic Stroke Patients - a Pivotal Study (THE "EMAGINE" STUDY)". This is a multicenter study that will be conducted at approximately 20 centers. BQ 2.0 is a wearable medical device that produces and delivers non-invasive, extremely-low-intensity and low-frequency, frequency-tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reduc...

What is the current status of trial NCT05044507?

This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2021-12-04. Estimated completion is 2024-01-16.

What conditions does trial NCT05044507 study?

This clinical trial studies the following conditions: Ischemic Stroke.

What interventions are being tested in trial NCT05044507?

The interventions under investigation include: BQ 2.0 (DEVICE).

Who is sponsoring clinical trial NCT05044507?

This trial is sponsored by BrainQ Technologies, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05044507 being conducted?

This trial has 15 study locations across California, District of Columbia, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ischemic Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.